Purple Biotech Appoints New CFO Amid Strategic Growth

The latest announcement is out from Purple Biotech ( (PPBT) ).

On May 12, 2025, Purple Biotech announced the appointment of Shai Lankry as Chief Financial Officer. Lankry brings over 20 years of financial leadership experience in the biotech and healthcare sectors, with a history of driving strategic growth and capital market execution. His appointment comes as Purple Biotech advances its pipeline into late-stage trials, potentially enhancing the company’s strategic partnerships and financial planning capabilities.

The most recent analyst rating on (PPBT) stock is a Buy with a $200.0000 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.

Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications with innovative approaches such as monoclonal antibodies and conditionally activated tri-specific antibodies. Headquartered in Rehovot, Israel, Purple Biotech is advancing its pipeline into late-stage trials, seeking strategic partnerships.

Average Trading Volume: 104,686

Technical Sentiment Signal: Sell

Current Market Cap: $6.08M

For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.